Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Sandra Navarra's publication output changed over time?
ScholarIQpublication output · 2004–2025
Output grew0% over the shown period — from 1 works in 2004 to 1 in 2025.
1
2
1
1
1
1
2
1
1
1
2004201120122015201620172018202120232025
What are the most-cited papers on Sandra Navarra?
ScholarIQmost cited works
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra Navarra, Renato Guzmán, A Gallacher, Stephen Hall, Roger A. Levy, Renato Jimenez, Edmund KM Li, Mathew Thomas, Ho‐Youn Kim, Manuel Gustavo Leon, C Tănăsescu, Е. Л. Насонов, Joung-Liang Lan, Lilia Pineda, Z. John Zhong, William W. Freimuth, Michelle Petri
The Lancet. 20112,071 Citations
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, Martin Aringer, Laurent Arnaud, Sang‐Cheol Bae, John Boletis, Ian N Bruce, Ricard Cervera, Andrea Doria, Thomas Dörner, Richard Furie, Dafna D. Gladman, Frédéric Houssiau, Luís Inês, David Jayne, Marios Kouloumas, László Kovács, Chi Chiu Mok, Eric F. Morand, Gabriella Moroni, Marta Mosca, Johanna Mücke, Chetan Mukhtyar, György Nagy, Sandra Navarra, Ioannis Parodis, José María Pego‐Reigosa, Michelle Petri, Bernardo A. Pons‐Estel, Matthias Schneider, Josef S Smolen, Elisabet Svenungsson, Yoshiya Tanaka, Maria G. Tektonidou, Y K Onno Teng, Anǵela Tincani, Edward M Vital, Ronald van Vollenhoven, Chris Wincup, George Βertsias, Dimitrios T. Boumpas
Annals of the Rheumatic Diseases. 2023995 CitationsOPEN ACCESS
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Kate Franklyn, Chak Sing Lau, Sandra Navarra, Worawit Louthrenoo, Aisha Lateef, Laniyati Hamijoyo, Cesarius Singgih Wahono, Shun Le Chen, Ou Jin, Susan Morton, Alberta Hoi, Molla Huq, Mandana Nikpour, Eric F. Morand
Annals of the Rheumatic Diseases. 2015747 Citations
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Susan Manzi, Jorge Sánchez‐Guerrero, Joan T. Merrill, Richard Furie, Dafna D. Gladman, Sandra Navarra, Ellen M. Ginzler, David D’Cruz, Andrea Doria, Simon Cooper, Z. John Zhong, Douglas R. Hough, William W. Freimuth, Michelle Petri
Annals of the Rheumatic Diseases. 2012409 CitationsOPEN ACCESS
Systematic review of the epidemiology of systemic lupus erythematosus in the Asia‐Pacific region: Prevalence, incidence, clinical features, and mortality
Rupert W. Jakes, Sang‐Cheol Bae, Worawit Louthrenoo, Chi‐Chiu Mok, Sandra Navarra, Namhee Kwon
Arthritis Care & Research. 2011376 Citations
Related on ScholarIQ
University of Santo Tomas Hospital
Institution
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Paper
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Paper
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Paper
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Paper
Systematic review of the epidemiology of systemic lupus erythematosus in the Asia‐Pacific region: Prevalence, incidence, clinical features, and mortality
Paper